-
1.发明公开
公开(公告)号：EP0925061A1
公开(公告)日：1999-06-30
申请号：EP97917593.0
申请日：1997-03-28
发明人： PARIKH, Indu , SELVARAJ, Ulagaraj
CPC分类号： A61K9/5123 , A61K9/145 , A61K9/5146 , A61K9/5192 , Y10S977/828 , Y10S977/883 , Y10S977/906 , Y10S977/915 , Y10S977/931
摘要： Submicron size particles of pharmaceutical or other water-insoluble or poorly water-insoluble substances are prepared using a combination of one or more surface modifiers/surfactants such as polaxomers, poloxamines, polyoxyethylene sorbitan fatty acid esters and the like together with natural or synthetic phospholipids. Particles so produced have a volume weighted mean particle size at least one-half smaller than obtainable using a phospolipid alone. Compositions so prepared are resistant to particle size growth on storage.
-
公开(公告)号：EP0855906A1
公开(公告)日：1998-08-05
申请号：EP96936782.0
申请日：1996-10-17
发明人： HENRIKSEN, Inge, B. , MISHRA, Awadesh, K. , PACE, Gary, W. , JOHNSTON, Keith, P. , MAWSON, Simon
CPC分类号： B01J3/008 , A61K9/14 , A61K9/145 , A61K9/146 , A61K9/1688 , B01F1/00 , B01F3/1214 , B01F3/1271 , B01F5/02 , B01F5/0287 , B01F2003/0064 , B01F2003/125 , B01F2215/0032 , Y02P20/544 , Y10S977/896 , Y10S977/906
摘要： Particles of water insoluble biologically active compounds, particularly water-insoluble drugs, with an average size of 100 nm to about 300 nm, are prepared by dissolving the compound in a solution then spraying the solution into compressed gaz, liquid or supercritical fluid in the presence of appropriate surface modifiers.
-
公开(公告)号：EP0799620A1
公开(公告)日：1997-10-08
申请号：EP97302298.1
申请日：1997-04-03
发明人： Parikh, Indu , Mishra, Awadhesh
CPC分类号： A61K9/1075 , A61K38/13 , Y10S514/938 , Y10S514/943
摘要： An oil-in-water emulsion composed of an aqueous phase and an oil phase which comprises a synthetic triglyceride in which is dissolved cyclosporin and phospholipid, and optionally free fatty acid or a salt thereof, provides a stable pharmaceutical composition.
-
公开(公告)号：EP0268222B1
公开(公告)日：1996-03-27
申请号：EP87116757.3
申请日：1987-11-13
IPC分类号： A61K47/00
CPC分类号： A01N25/02 , A01N37/18 , A01N43/60 , A61K9/0014 , A61K47/22 , C07D295/185 , D06M16/00 , D06P1/6426 , Y10S514/946 , Y10S514/947
-
公开(公告)号：EP0796616B1
公开(公告)日：1999-07-14
申请号：EP97301839.3
申请日：1997-03-19
发明人： HAYNES, Duncan
CPC分类号： A61K31/05 , A61K9/1075
-
公开(公告)号：EP0752882A1
公开(公告)日：1997-01-15
申请号：EP94926459.0
申请日：1994-01-24
CPC分类号： A61K38/1808 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0325 , A61K38/1841 , A61K38/2207 , A61K48/00 , A61K48/005 , C12N15/8509 , A61K2300/00
摘要： A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGF receptor ligand, e.g. TGFα, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGFα gene.
-
公开(公告)号：EP0268222A2
公开(公告)日：1988-05-25
申请号：EP87116757.3
申请日：1987-11-13
IPC分类号： A61K47/00
CPC分类号： A01N25/02 , A01N37/18 , A01N43/60 , A61K9/0014 , A61K47/22 , C07D295/185 , D06M16/00 , D06P1/6426 , Y10S514/946 , Y10S514/947
摘要： This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer having the structural formula
wherein X may represent sulfur, oxygen or nitrogen; a and b may be 0 or 1, c may be 0, 1 or 2, except that when X is oxygen, a, b and c are 0, when X is nitrogen c is 0 and only one of a or b is 1, and when X is sulfur a and b are0; A is a branched or a straight chain, divalent aliphatic radical having from 0 to 2 double bonds; Rʹ is selected from the group consisting of H, a lower alkyl group having from 1 to 4 carbon atoms, phenyl, lower alkyl or halogen substituted phenyl, acetamido, halogen, piperidinyl, lower alkyl or halogen substituted piperidinyl, carbalkoxy, carboxamide, and alkanoyl; and R is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms,
wherein Rʺ is H or halogen, and salts, e.g. acid or quaternary derivatives, thereof. These compositions are useful in topical or transdermal applications of the physiologically-active agent.摘要翻译： 本发明涉及一种在透皮装置或制剂中通过人和动物的皮肤或粘膜给予全身活性剂包括治疗剂的方法，所述方法包括向所述全身剂局部给药有效量的具有下列结构式的膜渗透促进剂：其中 X可以代表硫，氧或氮; a和b可以是0或1，c可以是0,1或2，除了当X是氧时，a，b和c是0时，当X是氮时，c是0且a或b中只有一个是1， 当X是硫时，a和b是0; A是具有0至2个双键的支链或直链二价脂族基团; R'选自H，具有1至4个碳原子的低级烷基，苯基，低级烷基或卤素取代的苯基，乙酰氨基，卤素，哌啶基，低级烷基或卤素取代的哌啶基，烷氧羰基，羧酰胺和烷酰基 ; 并且R是氢或具有1至4个碳原子的低级烷基，其中R“是H或卤素，和盐， 酸或季铵衍生物。 这些组合物可用于生理活性剂的局部或透皮应用。
-
8.发明公开
公开(公告)号：EP1054678A2
公开(公告)日：2000-11-29
申请号：EP99906801.8
申请日：1999-02-10
IPC分类号： A61K31/585 , A61K35/60 , A61K31/20
CPC分类号： A61K9/4858 , A61K9/0014 , A61K9/4891 , A61K31/00 , A61K31/20 , A61K31/58
摘要： Methods of treating inflammation of the gastrointestinal tract and/or systemic or local inflammation by administering a steroid anti-inflammatory or a non-steroid anti-inflammatory drug in conjunction with polyunsaturated fatty acids or their derivatives and optionally also a pharmacologically active antioxidant and compositions for practicing these methods are described.
-
公开(公告)号：EP0857059A1
公开(公告)日：1998-08-12
申请号：EP96923519.0
申请日：1996-06-26
发明人： PARIKH, Indu
CPC分类号： A61K39/39 , A61K47/544 , A61K2039/55555 , A61K2039/55583 , Y02A50/388 , Y02A50/466
摘要： An adjuvant for administration to a host animal to enhance immune response, comprising a polysaccharide-phospholipid conjugate, whose polysaccharide moiety may for example comprise a modified glucan, chitosan, or alginate polysaccharide, conjugated to a phospholipid. The adjuvant may be suitably formulated with an antigen to provide a therapeutic vaccine for a variety of disease states and/or physiological conditions.
-
公开(公告)号：EP0796616A1
公开(公告)日：1997-09-24
申请号：EP97301839.3
申请日：1997-03-19
发明人： HAYNES, Duncan
CPC分类号： A61K31/05 , A61K9/1075
摘要： Formulations ofphospholipid-coated microdroplets of propofol devoid of fats and triglycerides provide chronic sedation over extended periods of time without fat overload. Being free of nutrients that support bacterial growth, these microdroplet formulations are bacteriosatic and bactericidal (e.g. self-sterilizing) and thus have extended shelf life.
摘要翻译： 以下要求保护：（A）微滴（直径至200微米），其包含由磷脂稳定层包围的缺乏含有能够支持细菌生长的油的异丙酚球。 （B）抗微生物药物组合物，其包含：（a）通过超声处理，均化，微流化或其它方法产生的微滴（直径为至少至1μm的微滴），并且包含稳定防聚结的丙泊酚核心，并被 磷脂膜层（PML）; 和（b）可注射载体。 异丙酚的体积与PML的重量的比例至少为1.0ml / g。 该组合物没有脂肪和甘油三酸酯，并且含有至少3％（重量/体积）的异丙酚。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.015 秒)
